Clinical trials: Interdigitating Dendritic Cell Sarcoma
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004171
- Testing
- busulfan, cyclophosphamide, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Northwestern University
Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Large Cell Lymphoma Pilot Study III
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with…
- Trial name
- NCT00187070
- Testing
- Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Lymphoma
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003396
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Maryland, Baltimore
Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00389818
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- 14 sites in United States
- Volunteers
- 43 people
- Sponsor
- AIDS Malignancy Consortium
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well they work in treating patients with relapsed or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00601718
- Testing
- vorinostat, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and using drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002691
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Conventional therapy is effective for diffuse aggressive lymphomas and low grade lymphomas, but is limited by relapse occurs in 40 to 50% of subjects.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Transformed Lymphoma
- Trial name
- NCT00225212
- Testing
- Rituximab 375 mg/m2
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
DLBCL - Diffuse Large B Cell Lymphoma, Double Expressor Lymphoma
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Evaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
- Trial name
- NCT07511114
- Testing
- C-Pola-R-CHP+X, CR-CHOP
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Ruijin Hospital
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT00293345
- Testing
- gemcitabine hydrochloride, triapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Large B-cell Lymphoma, Relapse
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
- Conditions
- Large B-cell Lymphoma, Relapse, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- EPCOR+LONCA (NCT06919939)
- Testing
- Epcoritamab, Loncastuximab Tesirine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Miami
Lymphoma
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer cells in different ways.
- Trial name
- NCT01334502
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Peripheral T-cell Lymphoma NOS, Mycosis Fungoides
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Background: Some T-cell lymphomas and leukemias do not respond to standard treatment. Researchers hope to develop a treatment that works better than current treatments.
- Conditions
- Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03905135
- Testing
- rhIL-15, Avelumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Leukemia
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00118326
- Testing
- filgrastim, allogeneic bone marrow transplantation
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
This phase II trial is studying how well CCI-779 works in treating patients with relapsed or refractory chronic lymphocytic leukemia.
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00086840
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Leukemia
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
RATIONALE: Glutamine may help lessen neuropathy caused by chemotherapy. It is not yet known whether glutamine is more effective than a placebo in treating neuropathy caused by vincristine.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity
- Trial name
- NCT00365768
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Columbia University
Leukemia, Lymphoma
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
- Trial name
- NCT00077493
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- MedImmune LLC
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
This randomized phase II trial is studying rituximab and combination chemotherapy to see how well they work compared to oblimersen, rituximab, and combination chemotherapy in treating patients with advanced diffuse large B-cell…
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00080847
- Testing
- oblimersen sodium, rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- National Cancer Institute (NCI)